Arcutis Biotherapeutics, Inc. (ARQT) has announced preliminary unaudited product revenues for the fourth quarter of 2024, totaling approximately $63 million, and full-year revenues of about $160 million. The company has indicated its availability for meetings during the upcoming JPMorgan Healthcare Conference. Meanwhile, Amgen Inc. (RARE) has provided guidance for total revenue in 2025, estimating between $640 million and $670 million. The Phase 3 Orbit study for setrusumab (UX143), aimed at treating osteogenesis imperfecta, is progressing to its second interim analysis, expected in mid-2025. The first interim analysis did not achieve statistical significance in fracture reduction, with a p-value of 0.001. The next interim analysis is anticipated around late May 2025, while the final analysis is projected for the second half of 2025. Alvelestat has received a positive opinion for EU Orphan Drug designation, potentially aiding in future partnerships.